1
|
Joosse ME, Aardoom MA, Kemos P, Turner D, Wilson DC, Koletzko S, Martin-de-Carpi J, Fagerberg UL, Spray C, Tzivinikos C, Sladek M, Shaoul R, Roma-Giannikou E, Bronsky J, Serban DE, Ruemmele FM, Garnier-Lengline H, Veres G, Hojsak I, Kolho KL, Davies IH, Aloi M, Lionetti P, Hussey S, Veereman G, Braegger CP, Trindade E, Wewer AV, Hauer AC, de Vries ACH, Sigall Boneh R, Sarbagili Shabat C, Levine A, de Ridder L. Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN. Aliment Pharmacol Ther 2018; 48:523-537. [PMID: 29984520 DOI: 10.1111/apt.14893] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Revised: 02/08/2018] [Accepted: 06/11/2018] [Indexed: 02/05/2023]
Abstract
BACKGROUND Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-related inflammation and immune suppression, but data are limited due to their rare occurrence. AIM To identify and describe the most common causes of mortality, types of cancer and previous or current therapy among children and young adults with paediatric-onset IBD. METHODS Information on paediatric-onset IBD patients diagnosed with malignancy or mortality was prospectively collected via a survey in 25 countries over a 42-month period. Patients were included if death or malignancy occurred after IBD diagnosis but before the age of 26 years. RESULTS In total, 60 patients were identified including 43 malignancies and 26 fatal cases (9 due to cancer). Main causes of fatality were malignancies (n = 9), IBD or IBD-therapy related nonmalignant causes (n = 10; including 5 infections), and suicides (n = 3). Three cases, all fatal, of hepatosplenic T-cell lymphoma were identified, all were biologic-naïve but thiopurine-exposed. No other haematological malignancies were fatal. The 6 other fatal cancer cases included 3 colorectal adenocarcinomas and 3 cholangiocarcinomas (CCAs). Primary sclerosing cholangitis (PSC) was present in 5 (56%) fatal cancers (1 colorectal carcinoma, 3 CCAs and 1 hepatosplenic T-cell lymphoma). CONCLUSIONS We report the largest number of paediatric-onset IBD patients with cancer and/or fatal outcomes to date. Malignancies followed by infections were the major causes of mortality. We identified PSC as a significant risk factor for cancer-associated mortality. Disease-related adenocarcinomas were a commoner cause of death than lymphomas.
Collapse
|
2
|
Kernan R, Hussey S. The Role of Screening for Coeliac Disease in Asymptomatic Individuals. Ir Med J 2017; 110:646. [PMID: 29465836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Affiliation(s)
- R Kernan
- Department of Paediatric Gastroenterology, Our Lady-s Children's Hospital, Crumlin
| | - S Hussey
- Department of Paediatric Gastroenterology, Our Lady-s Children's Hospital, Crumlin
| |
Collapse
|
3
|
Hussey S. Editorial: changing nature of paediatric IBD-new insights from Irish data. Author's reply. Aliment Pharmacol Ther 2017; 46:458-459. [PMID: 28707793 DOI: 10.1111/apt.14192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
Affiliation(s)
- S Hussey
- National Centre for Paediatric Gastroenterology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| |
Collapse
|
4
|
Coughlan A, Wylde R, Lafferty L, Quinn S, Broderick A, Bourke B, Hussey S. A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45:1534-1541. [PMID: 28449214 DOI: 10.1111/apt.14070] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 05/11/2016] [Accepted: 03/10/2017] [Indexed: 01/08/2023]
Abstract
BACKGROUND The incidence of paediatric inflammatory bowel disease diagnosed before age 10 years is reportedly increasing, but national data are limited. AIM To characterise the epidemiology, phenotype and clinical outcomes of children diagnosed with inflammatory bowel disease before age 10 years, and compare with data from children diagnosed aged 10-16 years. METHODS A review of all Irish cases of early onset inflammatory bowel disease (diagnosis <10 years, EO-IBD) presenting between January 2000 and December 2014 was undertaken and compared to a cohort of later onset paediatric inflammatory bowel disease patients (diagnosis between 10 and 16 years, LO-IBD). Diagnostic investigations, phenotype, treatments, and long-term clinical and surgical outcomes were analysed. RESULTS One hundred and ninety children (99 male) with EO-IBD were identified; 92 (48%) CD, 77 (41%) UC and 21 (11%) IBDU. The incidence of EO-IBD increased by 0.6 per 100 000 per year (0.8-3.2 per 100 000 per year), with a significant increase in UC by 0.06 per 100 000 per year (P=.02). Males with CD had more upper GI disease (L4a; 48% vs 21%; P=.007), more extensive disease distribution (L3±L4; 31% vs 11%; P=.05) and more severe disease activity at presentation (52% vs 31%; P=.05) than females. Fewer patients with early onset than later onset Crohn's disease had ileocolonic disease (L3; 10% vs 20%; P<.001). More relapses were observed in the first year post-diagnosis in early onset than later onset IBD (1.02 vs 0.5 mean relapses; P<.001). CONCLUSIONS EO-IBD is increasing in incidence. Males have more extensive and severe disease phenotypes, and younger patients have higher relapse rates than older children. Further research to explain these findings is warranted.
Collapse
Affiliation(s)
- A Coughlan
- National Centre for Paediatric Gastroenterology (NCPG), OLCHC, Crumlin, Dublin, Ireland.,National Children's Research Centre, OLCHC, Crumlin, Dublin, Ireland
| | - R Wylde
- National Centre for Paediatric Gastroenterology (NCPG), OLCHC, Crumlin, Dublin, Ireland.,Leiden University Medical Centre, Leiden, The Netherlands
| | - L Lafferty
- National Centre for Paediatric Gastroenterology (NCPG), OLCHC, Crumlin, Dublin, Ireland
| | - S Quinn
- National Centre for Paediatric Gastroenterology (NCPG), OLCHC, Crumlin, Dublin, Ireland
| | - A Broderick
- National Centre for Paediatric Gastroenterology (NCPG), OLCHC, Crumlin, Dublin, Ireland.,Academic Centre for Paediatric Research, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
| | - B Bourke
- National Centre for Paediatric Gastroenterology (NCPG), OLCHC, Crumlin, Dublin, Ireland.,National Children's Research Centre, OLCHC, Crumlin, Dublin, Ireland.,Academic Centre for Paediatric Research, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
| | - S Hussey
- National Centre for Paediatric Gastroenterology (NCPG), OLCHC, Crumlin, Dublin, Ireland.,National Children's Research Centre, OLCHC, Crumlin, Dublin, Ireland.,Academic Centre for Paediatric Research, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.,Department of Paediatrics, Royal College of Surgeons of Ireland, Dublin, Ireland
| | -
- National Centre for Paediatric Gastroenterology (NCPG), OLCHC, Crumlin, Dublin, Ireland.,National Children's Research Centre, OLCHC, Crumlin, Dublin, Ireland
| |
Collapse
|
5
|
Kutty J, Hussey S, Broderick AM, Quinn S, Bourke B. HLA testing for coeliac disease in Ireland? Ir Med J 2015; 108:133. [PMID: 26062236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
6
|
Hope B, Shahdadpuri R, Dunne C, Broderick AM, Grant T, Hamzawi M, O'Driscoll K, Quinn S, Hussey S, Bourke B. Rapid rise in incidence of Irish paediatric inflammatory bowel disease. Arch Dis Child 2012; 97:590-4. [PMID: 22550323 DOI: 10.1136/archdischild-2011-300651] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
AIMS To describe the change in incidence of paediatric inflammatory bowel disease (IBD) observed at the National Centre for Paediatric Gastroenterology, Hepatology and Nutrition, and to determine whether the presenting disease phenotype and disease outcomes have changed during the past decade. METHODS The annual incidence of IBD in Irish children aged <16 years was calculated for the years 2000-2010. Two subsets of patients, group A (diagnosed between 1 January 2000 and 31 December 2001), and group B (diagnosed between 1 January and 31 December 2008) were phenotyped according to the Paris Classification. Phenotype at diagnosis and 2-year follow-up were then compared. RESULTS 406 new cases of IBD were identified. The incidence was 2.5/100 000/year in 2001, 7.3 in 2008 and 5.6 in 2010, representing a significant increase in the number of new cases of Crohn's disease (CD) and ulcerative colitis (UC). There were 238 cases of CD; 129 of UC; and 39 of IBD unclassified. Comparing groups A and B, no differences were found in disease location at diagnosis or, for CD, in its behaviour. CONCLUSIONS There has been a substantial and sustained increase in the incidence of childhood UC and CD in Ireland over a relatively short period of time. However, disease phenotype at diagnosis has not changed. At 2 years follow-up, CD appears to progress less frequently than in some neighbouring countries. These variations remain unexplained. Prospective longitudinal studies will help to elucidate further the epidemiology of childhood IBD.
Collapse
Affiliation(s)
- B Hope
- National Centre for Paediatric Gastroenterology, Hepatology and Nutrition, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Raju D, Hussey S, Ang M, Terebiznik M, Sibony M, Galindo-Mata E, Gupta V, Blanke S, Delgado A, Romero-Gallo J, Ramjeet M, Mascarenhas H, Peek R, Correa P, Streutker C, Hold G, Kunstmann E, Yoshimori T, Silverberg MS, Girardin S, Philpott D, El Omar E, Jones N. Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans. Gastroenterology 2012; 142:1160-71. [PMID: 22333951 PMCID: PMC3336037 DOI: 10.1053/j.gastro.2012.01.043] [Citation(s) in RCA: 162] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Revised: 01/03/2012] [Accepted: 01/26/2012] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS The Helicobacter pylori toxin vacuolating cytotoxin (VacA) promotes gastric colonization, and its presence (VacA(+)) is associated with more-severe disease. The exact mechanisms by which VacA contributes to infection are unclear. We previously found that limited exposure to VacA induces autophagy of gastric cells, which eliminates the toxin; we investigated whether autophagy serves as a defense mechanism against H pylori infection. METHODS We investigated the effect of VacA on autophagy in human gastric epithelial cells and primary gastric cells from mice. Expression of p62, a marker of autophagy, was also assessed in gastric tissues from patients infected with toxigenic (VacA(+)) or nontoxigenic strains. We analyzed the effect of VacA on autophagy in peripheral blood monocytes obtained from subjects with different genotypes of ATG16L1, which regulates autophagy. We performed genotyping for ATG16L1 in 2 cohorts of infected and uninfected subjects. RESULTS Prolonged exposure of human gastric epithelial cells and mouse gastric cells to VacA disrupted induction of autophagy in response to the toxin, because the cells lacked cathepsin D in autophagosomes. Loss of autophagy resulted in the accumulation of p62 and reactive oxygen species. Gastric biopsy samples from patients infected with VacA(+), but not nontoxigenic strains of H pylori, had increased levels of p62. Peripheral blood monocytes isolated from individuals with polymorphisms in ATG16L1 that increase susceptibility to Crohn's disease had reduced induction of autophagy in response to VacA(+) compared to cells from individuals that did not have these polymorphisms. The presence of the ATG16L1 Crohn's disease risk variant increased susceptibility to H pylori infection in 2 separate cohorts. CONCLUSIONS Autophagy protects against infection with H pylori; the toxin VacA disrupts autophagy to promote infection, which could contribute to inflammation and eventual carcinogenesis.
Collapse
Affiliation(s)
- D Raju
- Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada, Departments of Paediatrics and Physiology, University of Toronto, Toronto, ON, Canada
| | - S Hussey
- Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada, Departments of Paediatrics and Physiology, University of Toronto, Toronto, ON, Canada,Department of Immunology, University of Toronto, Toronto, ON Canada
| | - M Ang
- Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada, Departments of Paediatrics and Physiology, University of Toronto, Toronto, ON, Canada
| | - M.R. Terebiznik
- Department of Cell and Systems Biology, University of Toronto, Scarborough, ON, Canada
| | - M Sibony
- Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada, Departments of Paediatrics and Physiology, University of Toronto, Toronto, ON, Canada,Zane Cohen Centre for Digestive Diseases, IBD group, Mount Sinai Hospital, Toronto, ON
| | - E Galindo-Mata
- Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada, Departments of Paediatrics and Physiology, University of Toronto, Toronto, ON, Canada
| | - V Gupta
- Department of Microbiology and Institute for Genomic Biology, University of Illinois, Urbana, IL, USA
| | - S.R. Blanke
- Department of Microbiology and Institute for Genomic Biology, University of Illinois, Urbana, IL, USA
| | - A Delgado
- Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Centre, Nashville, TN
| | - J Romero-Gallo
- Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Centre, Nashville, TN
| | - M Ramjeet
- Department of Laboratory Medicine and Pathobiology, and the Li Ka Shing Knowledge Institute University of Toronto, Toronto, ON
| | - H Mascarenhas
- Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada, Departments of Paediatrics and Physiology, University of Toronto, Toronto, ON, Canada,Department of Immunology, University of Toronto, Toronto, ON Canada
| | - R.M. Peek
- Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Centre, Nashville, TN
| | - P Correa
- Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Centre, Nashville, TN
| | - C Streutker
- Department of Laboratory Medicine, St. Michaels’s Hospital, Toronto, ON
| | - G Hold
- Institute of Medical Sciences, School of Medicine and Dentistry, Aberdeen University, Foresterhill, Aberdeen
| | - E Kunstmann
- Praxis fur Humangenetik, Theodore-Boveri-Weg, University Wuerzburg, Germany
| | - T Yoshimori
- Department of Cellular Regulation, Research institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan
| | - M. S. Silverberg
- Zane Cohen Centre for Digestive Diseases, IBD group, Mount Sinai Hospital, Toronto, ON
| | - S.E. Girardin
- Department of Laboratory Medicine and Pathobiology, and the Li Ka Shing Knowledge Institute University of Toronto, Toronto, ON
| | - D.J. Philpott
- Department of Immunology, University of Toronto, Toronto, ON Canada
| | - E El Omar
- Institute of Medical Sciences, School of Medicine and Dentistry, Aberdeen University, Foresterhill, Aberdeen
| | - N.L. Jones
- Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada, Departments of Paediatrics and Physiology, University of Toronto, Toronto, ON, Canada,Corresponding Author Dr. Nicola Jones, Departments of Paediatrics and Physiology, University of Toronto, Cell Biology Program, Hospital for Sick Children, 555, University Avenue, Toronto, ON M5G1X8, Phone no: 416-813-7072,
| |
Collapse
|
8
|
Affiliation(s)
- D L Holznagel
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, 2015 Linden Drive, Madison, Wisconsin 53706, USA
| | | | | | | | | |
Collapse
|
9
|
Abstract
Early colonization of the infant gastrointestinal tract is crucial for the overall health of the infant, and establishment and maintenance of non-pathogenic intestinal microbiota may reduce several neonatal inflammatory conditions. Much effort has therefore been devoted to manipulation of the composition of the microbiota through 1) the role of early infant nutrition, particularly breast milk, and supplementation of infant formula with prebiotics that positively influence the enteric microbiota by selectively promoting growth of beneficial bacteria and 2) oral administration of probiotic bacteria which when administered in adequate amounts confer a health benefit on the host. While the complex microbiota of the adult is difficult to change in the long-term, there is greater impact of the diet on infant microbiota as this is not as stable as in adults. Decreasing excessive use of antibiotics and increasing the use of pre- and probiotics have shown to be beneficial in the prevention of several important infant diseases such as necrotizing enterocolitis and atopic eczema as well as improvement of short and long-term health. This review addresses how the composition of the gut microbiota becomes established in early life, its relevance to infant health, and dietary means by which it can be manipulated.
Collapse
Affiliation(s)
- R Wall
- Alimentary Pharmabiotic Centre (APC), Co. Cork, Ireland
- Teagasc, Moorepark Food Research Centre, Fermoy, Co. Cork, Ireland
- University College Cork, National University of Ireland, Ireland
| | - R.P Ross
- Alimentary Pharmabiotic Centre (APC), Co. Cork, Ireland
- Teagasc, Moorepark Food Research Centre, Fermoy, Co. Cork, Ireland
| | - C.A Ryan
- Department of Paediatrics and Child Health, University College Cork, Ireland
| | - S Hussey
- Department of Paediatrics and Child Health, University College Cork, Ireland
| | - B Murphy
- Department of Paediatrics and Child Health, University College Cork, Ireland
| | - G.F Fitzgerald
- Alimentary Pharmabiotic Centre (APC), Co. Cork, Ireland
- University College Cork, National University of Ireland, Ireland
| | - C Stanton
- Alimentary Pharmabiotic Centre (APC), Co. Cork, Ireland
- Teagasc, Moorepark Food Research Centre, Fermoy, Co. Cork, Ireland
| |
Collapse
|
10
|
Hussey S, Gander R, Southern P, Hoang M. Subcutaneous Phaeohyphomycosis Caused by Cladophialophora Bantiana. J Cutan Pathol 2008. [DOI: 10.1111/j.0303-6987.2005.320cy.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Rosberg-Cody E, Ross RP, Hussey S, Ryan CA, Murphy BP, Fitzgerald GF, Devery R, Stanton C. Mining the microbiota of the neonatal gastrointestinal tract for conjugated linoleic acid-producing bifidobacteria. Appl Environ Microbiol 2004; 70:4635-41. [PMID: 15294796 PMCID: PMC492392 DOI: 10.1128/aem.70.8.4635-4641.2004] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
This study was designed to isolate different strains of the genus Bifidobacterium from the fecal material of neonates and to assess their ability to produce the cis-9, trans-11 conjugated linoleic acid (CLA) isomer from free linoleic acid. Fecal material was collected from 24 neonates aged between 3 days and 2 months in a neonatal unit (Erinville Hospital, Cork, Ireland). A total of 46 isolates from six neonates were confirmed to be Bifidobacterium species based on a combination of the fructose-6-phosphate phosphoketolase assay, RAPD [random(ly) amplified polymorphic DNA] PCR, pulsed-field gel electrophoresis (PFGE), and partial 16S ribosomal DNA sequencing. Interestingly, only 1 of the 11 neonates that had received antibiotic treatment produced bifidobacteria. PFGE after genomic digestion with the restriction enzyme XbaI demonstrated that the bifidobacteria population displayed considerable genomic diversity among the neonates, with each containing between one and five dominant strains, whereas 11 different macro restriction patterns were obtained. In only one case did a single strain appear in two neonates. All genetically distinct strains were then screened for CLA production after 72 h of incubation with 0.5 mg of free linoleic acid ml(-1) by using gas-liquid chromatography. The most efficient producers belonged to the species Bifidobacterium breve, of which two different strains converted 29 and 27% of the free linoleic acid to the cis-9, trans-11 isomer per microgram of dry cells, respectively. In addition, a strain of Bifidobacterium bifidum showed a conversion rate of 18%/microg dry cells. The ability of some Bifidobacterium strains to produce CLA could be another human health-promoting property linked to members of the genus, given that this metabolite has demonstrated anticarcinogenic activity in vitro and in vivo.
Collapse
Affiliation(s)
- E Rosberg-Cody
- Biotechnology, Dairy Products Research Centre, Teagasc, Moorepark, Fermoy, County Cork, Ireland
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Sharif F, Hussey S, Gill D. The tale of a blue toddler. Ir Med J 2003; 96:248-9. [PMID: 14653384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
|
13
|
Wilson WD, Mihalyi JE, Hussey S, Lunn DP. Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and influenza and their effect on the response of foals to vaccination. Equine Vet J 2001; 33:644-50. [PMID: 11770984 DOI: 10.2746/042516401776249435] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Influenza and tetanus-specific antibodies of the IgG sub-isotypes are posively transferred to foals via colostrum and inhibit their response to inactivated influenza vaccines and tetanus toxoid. High titres of influenza antibodies of IgGa and IgGb subisotypes and tetanus antibodies of the IgGa, IgGb and IgG(T) subisotypes were detected in postsucking serum samples collected from foals born to mares that had received booster doses of multicomponent vaccines during the last 2 months of gestation. Thereafter, titres declined in an exponential manner but were still detectable in all foals at age 26 weeks, regardless of whether they had been vaccinated prior to age 26 weeks. Mean +/- s.e. half-life of decline of influenza IgGa antibodies (27.0 +/- 2.3 days) was significantly shorter than that of influenza IgGb antibodies (39.1 +/- 2.7 days; P<0.005). Tetanus IgGa and IgGb antibodies declined with half-lives of 28.8 +/- 3.0 and 34.8 +/- 5.1 days, respectively. Titres of tetanus IgG(T) antibodies were substantially higher than those of influenza IgG(T) antibodies in postsucking samples and remained so through age 26 weeks, declining with a half-life of approximately 35 days. Postsucking titres of tetanus and influenza antibodies of the IgA isotype were low and declined rapidly to undetectable levels. Yearlings showed significant increases in titre of influenza IgGa, IgGb and IgG(T) subisotype antibodies but no increase in influenza IgA antibodies in response to 2 doses of multicomponent vaccines containing tetanus toxoid and inactivated influenza A-1 and A-2 antigens. Yearlings also showed strong tetanus IgGa, IgGb and IgG(T) subisotype responses to one dose of vaccine and a substantial further rise in titre in response to administration of a second dose 3 weeks later, but failed to show an increase in titre of tetanus IgA antibodies. The influenza and tetanus IgGa, IgGb and IgG(T) subisotype responses of 6-month-old foals to vaccination followed the same pattern as those shown by yearlings but titres were generally lower. In contrast, 3-month-old foals failed to show increases in titre of either influenza or tetanus IgG subisotypes in response to 2 doses of vaccine and generally needed 1-3 additional booster doses of vaccine to achieve titres similar to those achieved by yearlings after 2 doses. Based on the finding that maternal antibodies exert a significant inhibitory effect on the response of foals to tetanus toxoid and inactivated influenza antigens, it is recommended that primary immunisation of foals born to vaccinated mares should not commence before age 6 months.
Collapse
Affiliation(s)
- W D Wilson
- Department of Medicine and Epidemiology (VM:VME), School of Veterinary Medicine, University of California, Davis 95616, USA
| | | | | | | |
Collapse
|
14
|
Chambers TM, Holland RE, Tudor LR, Townsend HG, Cook A, Bogdan J, Lunn DP, Hussey S, Whitaker-Dowling P, Youngner JS, Sebring RW, Penner SJ, Stiegler GL. A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine Vet J 2001; 33:630-6. [PMID: 11770982 DOI: 10.2746/042516401776249291] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Flu Avert IN vaccine is a new, live attenuated virus vaccine for equine influenza. We tested this vaccine in vivo to ascertain 1) its safety and stability when subjected to serial horse to horse passage, 2) whether it spread spontaneously from horse to horse and 3) its ability to protect against heterologous equine influenza challenge viruses of epidemiological relevance. For the stability study, the vaccine was administered to 5 ponies. Nasal swabs were collected and pooled fluids administered directly to 4 successive groups of naïve ponies by intranasal inoculation. Viruses isolated from the last group retained the vaccine's full attenuation phenotype, with no reversion to the wild-type virus phenotype or production of clinical influenza disease. The vaccine virus spread spontaneously to only 1 of 13 nonvaccinated horses/ponies when these were comingled with 39 vaccinates in the same field. For the heterologous protection study, a challenge model system was utilised in which vaccinated or naïve control horses and ponies were exposed to the challenge virus by inhalation of virus-containing aerosols. Challenge viruses included influenza A/equine-2/Kentucky/98, a recent representative of the 'American' lineage of equine-2 influenza viruses; and A/equine-2/Saskatoon/90, representative of the 'Eurasian' lineage. Clinical signs among challenged animals were recorded daily using a standardised scoring protocol. With both challenge viruses, control animals reliably contracted clinical signs of influenza, whereas vaccinated animals were reliably protected from clinical disease. These results demonstrate that Flu Avert IN vaccine is safe and phenotypically stable, has low spontaneous transmissibility and is effective in protecting horses against challenge viruses representative of those in circulation worldwide.
Collapse
Affiliation(s)
- T M Chambers
- Department of Veterinary Science, University of Kentucky, Lexington 40546-0099, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Lunn DP, Hussey S, Sebing R, Rushlow KE, Radecki SV, Whitaker-Dowling P, Youngner JS, Chambers TM, Holland RE, Horohov DW. Safety, efficacy, and immunogenicity of a modified-live equine influenza virus vaccine in ponies after induction of exercise-induced immunosuppression. J Am Vet Med Assoc 2001; 218:900-6. [PMID: 11294315 DOI: 10.2460/javma.2001.218.900] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To determine safety, efficacy, and immunogenicity of an intranasal cold-adapted modified-live equine influenza virus vaccine administered to ponies following induction of exercise-induced immunosuppression. DESIGN Prospective study. ANIMALS Fifteen 9- to 15-month old ponies that had not had influenza. PROCEDURE Five ponies were vaccinated after 5 days of strenuous exercise on a high-speed treadmill, 5 were vaccinated without undergoing exercise, and 5 were not vaccinated or exercised and served as controls. Three months later, all ponies were challenged by nebulization of homologous equine influenza virus. Clinical and hematologic responses and viral shedding were monitored, and serum and nasal secretions were collected for determination of influenza-virus-specific antibody isotype responses. RESULTS Exercise caused immunosuppression, as indicated by depression of lymphocyte proliferation in response to pokeweed mitogen. Vaccination did not result in adverse clinical effects, and none of the vaccinated ponies developed clinical signs of infection following challenge exposure. In contrast, challenge exposure caused marked clinical signs of respiratory tract disease in 4 control ponies. Vaccinated and control ponies shed virus after challenge exposure. Antibody responses to vaccination were restricted to serum IgGa and IgGb responses in both vaccination groups. After challenge exposure, ponies in all groups generated serum IgGa and IgGb and nasal IgA responses. Patterns of serum hemagglutination inhibition titers were similar to patterns of IgGa and IgGb responses. CONCLUSIONS AND CLINICAL RELEVANCE Results suggested that administration of this MLV vaccine to ponies with exercise-induced immunosuppression was safe and that administration of a single dose to ponies provided clinical protection 3 months later.
Collapse
Affiliation(s)
- D P Lunn
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999; 130:510-4. [PMID: 10075619 DOI: 10.7326/0003-4819-130-6-199903160-00015] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Hypericin, the active compound in St. John's Wort, has antiretroviral activity in vitro. Many HIV-infected persons use St. John's wort. OBJECTIVE To evaluate the safety and antiretroviral activity of hypericin in HIV-infected patients. DESIGN Phase I study. SETTING Four clinical research units. PATIENTS 30 HIV-infected patients with CD4 counts less than 350 cells/mm3. INTERVENTION Intravenous hypericin, 0.25 or 0.5 mg/kg of body weight twice weekly or 0.25 mg/kg three times weekly, or oral hypericin, 0.5 mg/kg daily. MEASUREMENTS Safety was assessed at weekly visits. Antiretroviral activity was assessed by changes in HIV p24 antigen level, HIV titer, HIV RNA copies, and CD4 cell counts. RESULTS Of the 30 patients who were enrolled, 16 discontinued treatment early because of toxic effects. Severe cutaneous phototoxicity was observed in 11 of 23 (48% [95% CI, 27% to 69%]) evaluable patients, and dose escalation could not be completed. Virologic markers and CD4 cell count did not significantly change. CONCLUSIONS Hypericin caused significant phototoxicity and had no antiretroviral activity in the limited number of patients studied.
Collapse
Affiliation(s)
- R M Gulick
- New York University Medical Center, New York, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker CS. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:235-46. [PMID: 8898668 DOI: 10.1097/00042560-199611010-00005] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A phase-I study was conducted to examine the safety, pharmacokinetics, and activity of combination 2',3'-dideoxyinosine (ddI) and ribavirin against human immunodeficiency virus type 1 (HIV-1)-positive individuals with CD4+ cell counts of < or = 500/microliter. Nineteen patients were enrolled into the study in which ddI monotherapy (200 mg p.o.b.i.d.) was administered for the first 4 weeks, followed by the coadministration of ribavirin (600 mg p.o.q.d.) and ddI (200 mg p.o.b.i.d.) for 8 or 20 additional weeks. The combination regimen was safe and well tolerated. Three patients did not complete 12 weeks of the study because of adverse events or voluntary withdrawal. The pharmacokinetic studies performed at weeks 4, 6, and 12 on specimens collected from the 15 individuals who completed 12 weeks of therapy revealed no pharmacokinetic interaction between ddI and ribavirin. A significant decline from baseline in HIV-1 titer as measured by quantitative HIV-1 culture was detected both during the ddI-monotherapy phase (week 4, p < 0.001) and during the combination-therapy ddI + ribavirin phase (week 12, p < 0.001); the median drop observed was 0.90 log10 at week 4 and 0.92 log10 at week 12. While the addition of ribavirin did not result in further reductions in viremia in the following weeks on study treatment, 13 (81%) of the 16 patients had at least a -0.5 log10 change in viral titer at week 12. The median decline in plasma viral RNA was 0.68 log10 at week 4(p < 0.001) and 0.67 log10 at week 12 (p = 0.005). CD4+ cell counts increased above baseline significantly during the ddI-monotherapy phase of the study (p = 0.0038). The median increase was +26 cells/mm3 at week 4 and +11 cells/mm3 at week 12; for patients who remained on treatment through 24 weeks, the median CD4+ cell count increase was +10 cells/mm3. The L74V ddI resistance-conferring HIV-I reverse-transcriptase mutation emerged in 53% of the patients. Patients with non-syncytium-inducing HIV variants demonstrated greater responses to treatment with larger decreases in virus load and greater increases in CD4+ cell count. Our results reveal that the combination of ddI and ribavirin in HIV-positive patients is safe, well tolerated, without adverse pharmacologic interaction, and associated with significant and sustained declines in virus load over 12 weeks of therapy.
Collapse
Affiliation(s)
- A J Japour
- Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
Fitts' Law was applied to the evaluation of discrete aimed arm movements in one dimension performed by 6 adults with cerebral palsy and 6 adults with normal movement. Targets (1.27, 3.81, 6.35, 8.89 cm in width) placed at distances of 20.32, 30.48, 40.64, and 50.80 cm provided Indices of Difficulty of 2.19 to 6.32 bits. A video game was used for the signal to move. The t tests for corrected means showed that the cerebral palsied group had greater reaction and movement times than than the normal group. Linear regression analyses for pooled data and for the individual cerebral palsied subjects showed (a) no relationship between reaction time and Index of Difficulty for either group and (b) a negative, linear relationship between reaction time and Index of Difficulty for 1 cerebral palsied subject. Movement time was linearly and positively related to the Index of Difficulty for the normal group but not for the cerebral palsied group. Two cerebral palsied subjects had movement times which conformed to Fitts' Law. While the exceptions to Fitts' Law may be due to the limited range of movement and spasticity caused by severe cerebral palsy, there are indications that two of the cerebral palsied subjects were performing ballistic rather than visually guided aimed movements. Fitts' Law may still apply when the distances and target positions are individualized to conform to subjects' specific limitations and when the signal to move is auditory rather than visual.
Collapse
Affiliation(s)
- P E Bravo
- Department of Psychology, California State University, Sacramento 95819-6007
| | | | | | | |
Collapse
|
19
|
Hussey S, Gibson PH, Elton RA, Yates CM, Christie JE, Eagles PA, Gordon A. Solubility of neurofibrillary tangles and ultrastructure of paired helical filaments in sodium dodecylsulphate. Acta Neuropathol 1988; 75:495-501. [PMID: 2967617 DOI: 10.1007/bf00687137] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Temporal cortex from 14 cases of Alzheimer-type dementia and 6 cases of Down's syndrome, all selected for severe Alzheimer pathology, was homogenised in distilled water, NaOH, or sodium dodecylsulphate (SDS) containing 0.1% beta-mercaptoethanol. The homogenates were stained with Congo red, and the neurofibrillary tangles and plaque cores were counted under crossed-polarisation microscopy. The number of tangles and plaque cores in the water-treated extracts was not related to age, sex, post-mortem interval or duration of dementia. The number of tangles after extraction in SDS or NaOH, as a percentage of tangles in water-treated extracts, was 57 +/- 25 (mean +/- SD) for 1% SDS, 43 +/- 17 for 5% SDS and 37 +/- 22 for 0.2 M NaOH. Plaque cores were essentially insoluble in all three agents. The percentage of tangles insoluble in 1% SDS did not correlate with age or post-mortem interval but decreased with increasing duration of dementia. Enhanced tangle solubility with increasing duration of dementia suggests that the nature of tangles changes with time; one possibility is that this reflects transformation of intracellular to extracellular tangles. Paired helical filament (PHF) length and the number of repeats per PHF were measured in electron micrographs of PHF prepared with and without treatment by 1% SDS. There was no significant multimodality of PHF length to suggest that PHF broke at regular intervals. The mean repeat length (PHF length/number of repeats) was greater for PHF isolated in the presence of 1% SDS than in its absence, showing that SDS affects ultrastructure by untwisting PHF.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- S Hussey
- MRC Brain Metabolism Unit, Edinburgh University Department of Pharmacology, UK
| | | | | | | | | | | | | |
Collapse
|
20
|
Crumpacker C, Heagy W, Bubley G, Monroe JE, Finberg R, Hussey S, Schnipper L, Lucey D, Lee TH, McLane MF. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation. Ann Intern Med 1987; 107:664-74. [PMID: 3662279 DOI: 10.7326/0003-4819-107-5-664] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
STUDY OBJECTIVE To assess safety, tolerance, and the clinical and laboratory effects of oral ribavirin in patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. DESIGN Three uncontrolled phase I trials of increasing duration: 14 days, 8 weeks, and 12 months. SETTING Outpatient clinic of a university-referral hospital. PATIENTS All patients were antibody-positive for the human immunodeficiency virus (HIV) by radioimmunoprecipitation assay, all had recovered from Pneumocystis carinii pneumonia, and none had Kaposi sarcoma at entry. Nine of ten patients with AIDS had less than 100 CD4+ lymphocytes/mm3 at entry and all patients with the AIDS-related complex had fewer than 200 CD4+ lymphocytes/mm3. Five patients with AIDS and five with the AIDS-related complex entered the 14-day trial. All but two patients with AIDS went on to the 8-week trial, along with seven additional patients with AIDS. Five surviving patients with AIDS and 3 patients with the AIDS-related complex went on to the 1-year study. INTERVENTIONS Oral ribavirin, 1200 mg twice daily for 3 days was given, followed by 300 mg twice daily for 11 days. During an 8-week trial, a loading dose of oral ribavirin was administered for 3 days, followed by a dose of 300 mg twice daily for 8 weeks. Prolonged regimen of a 3-day loading dose was given, followed by a dose of 300 mg twice daily for 1 year. MEASUREMENTS AND MAIN RESULTS Ribavirin treatment was well tolerated, with anemia requiring transfusion in one of the ten patients with AIDS receiving the drug for 8 weeks; no other significant toxicity occurred. Six of nine patients initially positive for HIV-1 in blood became negative during ribavirin treatment. Six of nine patients with AIDS had a twofold improvement in lymphoproliferative response to at least one lectin with ribavirin treatment. Mean survival from first episode of P. carinii pneumonia was 17.3 months in patients with AIDS receiving 8 weeks of ribavirin and 21.2 months in patients with AIDS receiving prolonged treatment. CONCLUSIONS Oral ribavirin, 600 mg daily, was well tolerated and safe in the patients with severe AIDS and the AIDS-related complex. Ribavirin therapy merits extensive evaluation in a multicenter controlled trial to assess its efficacy.
Collapse
Affiliation(s)
- C Crumpacker
- Divisions of Infectious Diseases, Harvard Thorndike-Dana Research Laboratory, Boston, Massachusetts
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ramirez LF, McCormick RA, Hull A, Hussey S. The effect of computerized utilization review on patterns of psychiatric inpatient care. Hosp Community Psychiatry 1987; 38:977-82. [PMID: 3119455 DOI: 10.1176/ps.38.9.977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
An interactive computerized utilization review system for psychiatric inpatient care was developed and tested on a 30-bed acute admission ward, where staff were trained in its use. The program permitted staff to review clinical decisions affecting length of stay and to receive immediate feedback on the cost and revenue for each case. The impact of the system was evaluated by comparing the length of stay of patients on the study unit with that of patients on a similar unit where the system was not in use, and also by comparing the length of stay for both units before and after the system was implemented. The findings showed that the length of stay on the study unit was significantly reduced after the system's implementation, and that it was well accepted by the staff. Six-month follow-up data showed no increase in symptomatology for the study patients compared with the control group.
Collapse
Affiliation(s)
- L F Ramirez
- Case Western Reserve University School of Medicine, Cleveland, Ohio
| | | | | | | |
Collapse
|
22
|
Hussey S, Yates CM, Christie JE, Elton RA, Gordon A. Alzheimer-type dementia and Down's syndrome: solubility of neurofibrillary tangles is related to duration of dementia. J Neurol Neurosurg Psychiatry 1987; 50:823-4. [PMID: 2956365 PMCID: PMC1032103 DOI: 10.1136/jnnp.50.6.823] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
23
|
|
24
|
Hussey S, Yates CM, Fink G. Fluorescence activated cell sorting (FACS) as a separation method for neurofibrillary tangles in Alzheimer's disease. J Neurosci Methods 1986; 16:1-8. [PMID: 2422499 DOI: 10.1016/0165-0270(86)90002-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We have developed a fluorescence cell sorting (FACS) method for the separation of neurofibrillary tangles from post-mortem brain from cases of Alzheimer's disease and Down's syndrome. Neurofibrillary tangles in brain homogenate were selectively labelled with the fluorescent dye congo red. Using FACS the tangles were separated from other tissue components on the basis of fluorescence and forward-angle light scatter to give a fraction highly enriched in tangles, which were identified by light and crossed polarisation microscopy. Tangles were not observed in a comparison fraction, collected at the same time, of weakly fluorescent particles of similar size to the tangles. Thus FACS provides a non-denaturing method for obtaining preparations of neurofibrillary tangles for purposes of further analysis.
Collapse
|
25
|
Kohanna FH, Sweeney J, Hussey S, Zacharski LR, Salzman EW. Effect of perioperative low-dose heparin administration on the course of colon cancer. Surgery 1983; 93:433-8. [PMID: 6829011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
There is evidence that drugs that inhibit blood coagulation or platelet activity may retard or prevent the recurrence of cancer in experimental animals and in patients. The data for 230 patients who underwent surgical resection for primary adenocarcinoma of the colon (Dukes B and C) during 1973 to 1977 were studied retrospectively to determine whether low-dose heparin given for prophylaxis of thromboembolism altered the interval to or prevalence of recurrence. Perioperative low-dose subcutaneous heparin was given to 180 patients, and 50 patients received no heparin. The groups were comparable in age, sex, extent of disease, and use of adjuvant chemotherapy or radiation therapy. Disease recurred in 54 of 180 patients (30%) who received heparin and 18 of 50 patients (36%) who did not receive heparin. This difference was not significant (chi2 = 0.6551, P = 0.418). The interval from surgery to recurrence of cancer was slightly longer in the heparin group (790 days) than in the nonheparin group (638 days), but this difference was not statistically significant (P = 0.268). Life table analysis revealed a significantly lower overall mortality rate among patients who received heparin (P less than 0.05), although there was no difference between the two groups in rate of deaths from colon cancer.
Collapse
|
26
|
|